Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sting-Kill is an over-the-counter (OTC) topical anesthetic and antipruritic treatment developed and marketed by CrossingWell Consumer Health (formerly Randob Labs). It is specifically formulated to provide temporary relief from pain and itching caused by insect stings (such as bees and wasps), insect bites (including mosquitoes, chiggers, ants, and spiders), and jellyfish stings. The product contains two primary active ingredients: benzocaine USP 20%, which acts as a local anesthetic by blocking voltage-gated sodium channels to inhibit pain signaling, and menthol USP 1%, which provides a cooling sensation and relieves itching through its interaction with TRPM8 receptors. Sting-Kill is available in convenient application formats, including single-use swabs and disposable wipes, and is FDA-approved for use in adults and children aged 2 and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sting-Kill.